Zio ECG Utilization Software (ZEUS) System vs KardiaAI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by iRhythm Technologies
VS
by AliveCor

AI Verdict

ZEUS is a comprehensive, cloud-based system for continuous ECG monitoring using proprietary wearable biosensors, providing end-to-end arrhythmia detection and reporting. KardiaAI, conversely, is an FDA-cleared AI software library designed for integration into other mobile apps and web platforms, offering on-demand analysis of ambulatory ECG rhythms for various cardiac conditions. While both leverage AI for cardiac rhythm analysis, ZEUS provides a complete monitoring solution, whereas KardiaAI offers a flexible AI engine for integration.

Choose Zio ECG Utilization Software (ZEUS) System if…

Choose the Zio ECG Utilization Software (ZEUS) System if you require a comprehensive, end-to-end solution for continuous, long-term ECG monitoring and arrhythmia diagnosis. This system is ideal for healthcare providers who need detailed, AI-analyzed reports over an extended period (up to 14 days) from a dedicated wearable biosensor to capture intermittent or elusive cardiac events and integrate seamlessly with EHRs.

View Zio ECG Utilization Software (ZEUS) System →

Choose KardiaAI if…

Choose KardiaAI if you need to integrate medical-grade, AI-powered ECG analysis capabilities into existing or new ambulatory ECG devices, mobile applications, or web platforms. This solution is best suited for developers or healthcare providers looking to enhance their current systems with on-demand or short-duration rhythm detection for conditions like AFib, bradycardia, and tachycardia through an API library.

View KardiaAI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Zio ECG Utilization Software (ZEUS) System KardiaAI
Pricing Unknown Subscription-based for advanced features and services.
Deployment Cloud-based. Mobile app, cloud-based.
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio ECG Utilization Software (ZEUS) System

Tool A, the Zio ECG Utilization Software (ZEUS) System, offers a dedicated ZioSuite web portal and mobile application specifically designed for healthcare professionals, providing a complete and streamlined user experience for managing cardiac monitoring. Tool B, KardiaAI, is primarily described as an AI software library for integration, implying its direct usability is for developers, although it powers user-facing applications.

Clinical Value

Zio ECG Utilization Software (ZEUS) System

Tool A provides continuous ECG data analysis for up to 14 days from wearable Zio monitors, utilizing proprietary deep-learned algorithms to generate comprehensive end-of-wear reports. This extended, continuous monitoring offers a higher likelihood of capturing intermittent arrhythmias and provides more in-depth diagnostic insights compared to Tool B, which focuses on detecting a range of specific conditions from ambulatory ECG rhythms.

Pricing & Value

KardiaAI

Tool B, KardiaAI, offers transparent, publicly available subscription-based pricing with clear tiers (e.g., KardiaCare Monthly, Annual, Plus). In contrast, Tool A requires contacting the company for pricing, making its value proposition less transparent and harder to assess without direct inquiry.

Enterprise Readiness

Zio ECG Utilization Software (ZEUS) System

Tool A is a cloud-based platform (AWS EC2) with explicit HL7-based EHR integration, indicating a robust and ready-to-deploy solution for enterprise healthcare systems. While Tool B is an FDA-cleared Software as a Medical Device (SaMD) and an API library suitable for integration, Tool A presents a more complete, out-of-the-box enterprise solution for comprehensive cardiac monitoring workflows.

Innovation

Zio ECG Utilization Software (ZEUS) System

Tool A's innovation lies in its combination of AI-powered, deep-learned algorithms with continuous, long-term (up to 14 days) ECG data analysis from wearable biosensors, providing a comprehensive system for advanced diagnostic depth. While Tool B innovates by offering medical-grade AI analysis as a flexible API library for broad integration, Tool A's approach to extended, in-depth diagnostic monitoring represents a significant advancement in clinical capability.

Support & Docs

Tie

Both tools demonstrate strong commitments to support and documentation. iRhythm Technologies (Tool A) provides comprehensive Instructions for Use, Clinical Reference Manuals, FAQs, and direct customer care via phone and email. AliveCor (Tool B) also offers extensive user manuals for its app and devices, a detailed FAQ section, and customer support via email and phone with specified hours. Based on available information, neither tool clearly surpasses the other in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Zio ECG Utilization Software (ZEUS) System KardiaAI
Product Name Zio ECG Utilization Software (ZEUS) System KardiaAI
Company iRhythm Technologies AliveCor
Primary Function AI-powered, cloud-based platform for analyzing continuous ECG data from wearable Zio monitors to aid physicians in diagnosing and managing cardiac arrhythmias. FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia.
Key AI Capabilities / Detections AI algorithm for arrhythmia detection and classification; proprietary deep-learned algorithms; continuous ECG data analysis (up to 14 days). Detection of atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, Sinus Rhythm with Supraventricular Ectopy (SVE); ECG noise filtering and noisy ECG detection.
Integration Integration with Zio wearable biosensors (Zio monitor, Zio Watch); HL7-based EHR integration. API library for integration into other ECG devices and software.
Specialties Cardiology, Family Medicine, Internal Medicine Cardiology, Emergency Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Zio ECG Utilization Software (ZEUS) System and KardiaAI.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The Zio ECG Utilization Software (ZEUS) System analyzes continuous ECG data for up to 14 days, collected from iRhythm's proprietary Zio wearable biosensors. KardiaAI is an AI software library that analyzes ambulatory ECG rhythms and can be integrated into various ECG devices and software via an API library.
ZEUS utilizes an AI algorithm for arrhythmia detection and classification from continuous ECG data. KardiaAI specifically detects atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, and Sinus Rhythm with Supraventricular Ectopy (SVE).
The ZEUS System is a cloud-based platform with a ZioSuite web portal and mobile application, offering HL7-based EHR integration. KardiaAI is a Software as a Medical Device (SaMD) provided as an API library for integration into other mobile apps and web platforms, and also offers EHR integration.
The ZEUS System is integrated with and analyzes data exclusively from iRhythm's proprietary Zio wearable biosensors, including the Zio monitor and Zio Watch. KardiaAI is an API library designed for integration into other ECG devices and software, and can be used with Kardia personal EKG devices like KardiaMobile.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.